Further pilot studies have been testing glioma antigen peptides in combination with imiquimod and Poly-ICLC (Hiltonol®), which is a TLR-3 agonist against recurrent ependymomas (NCT01795313) and pediatric glioma (NCT01130077), respectively. The gene discussed is TLR3; the disease is central nervous system cancer.